The Biotech Startups Podcast 🧬 The Founder Identity Trap: Navigating the Hidden Mental Cost of Leadership | Nicole Paulk (Part 4/4)
Apr 9, 2026
42:03
🧬 The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing. Skip the upfront costs, stay lean, and focus on breakthrough science.
As a TBSP listener, you can get exclusive perks through Excedr’s partner network—special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners.
"Not wrapping your entire self-worth up in whether or not your company works — that is a learned skill."
In this episode of The Biotech Startups Podcast, Siren Biotechnology CEO & Founder, Nicole Paulk unpacks why being a first-time female technical academic founder CEO — "the worst possible thing you could be" — was actually the best CEO training imaginable. She breaks down how her scrappy academic mindset stretched a $6M seed round across three and a half years, why going all-in on unglamorous CMC optimization was Siren Biotechnology's most important early decision, and why capital efficiency is a company-defining mindset, not just a financial strategy. Nicole also opens up about the loneliness of the founder CEO role, the toxic culture of "competitive complaining" at industry meetups, and the profound weight of Siren's recent FDA IND clearance — and what it means to be on the verge of dosing the very first brain cancer patient at UCSF.
Key topics covered:
- Academic Founders as CEOs: Why scrappy scientists make the best capital-efficient startup builders
- Stretching Capital: How Siren's $6M seed lasted three and a half years — and why a long runway forces better science
- CMC as a Competitive Advantage: Why early investment in unglamorous manufacturing optimization can make or break your company
- Founder Mental Health & Loneliness: The risks of tying your identity to your company and why "competitive complaining" is toxic for the industry
- Siren's FDA IND Milestone: The profound weight of becoming clinical-stage and nearing the first brain cancer patient dose
If you enjoy The Biotech Startups Podcast, please consider subscribing, leaving a review, or sharing it with your friends. Thanks for listening.
Subscribe to the Podcast:
Find our guest, Nicole Paulk at these links:
LinkedIn: https://www.linkedin.com/in/nicolepaulk/
Website: https://sirenbiotechnology.com/
Find our host, Jon Chee, at these links:
LinkedIn: https://www.linkedin.com/in/jonchee
Learn more about Excedr:
LinkedIn: https://www.linkedin.com/company/excedr/
Website: https://www.excedr.com
Intro & Outro Songs Created by OkKyojin, Owned by Excedr:
Website: https://flow.page/kyojin
Resources & Articles:
Lean Startup Principles for Founders:
IND (Investigational New Drug) Application Basics:
Founder Burnout and Mental Health in Startups:
Companies, Universities, & People mentioned:
Silicon Valley Bank (SVB): https://www.svb.com
Founders Fund: https://foundersfund.com
Timestamps:
00:00 Intro
02:24 Why Being a First-Time Female Academic Founder CEO Is the Best CEO Training
09:59 Making a Small Seed Round Last: How $6M Stretched Three and a Half Years
11:00 The Case for Capital Efficiency and Thoughtful Science
16:23 The Problem with Founder "Bitch-Fest" Meetups
19:16 A Better Model: Solution-Focused Founder Gatherings
22:11 The Loneliness of the Founder CEO and Mental Health
23:54 Knowing When to Dial It Up and Dial It Back
26:23 Building Community Without Competitive Complaining
29:54 Advice to Her 21-Year-Old Self: Follow the Weird Little Sprites
33:04 Shoutouts and Gratitude
34:20 Siren's FDA IND Clearance and the First Patient on the Horizon
38:40 Outro
The Biotech Startups Podcast gives you a front-row seat to the business and science of building a biotech. Hosted by Jon Chee, CEO of Excedr, the show features honest conversations with founders, execs, and investors about their work, their companies, and how they got there. From scientific breakthroughs to startup lessons, each episode explores what it really takes to grow a life science company—from pre-seed to IPO.